Switch theme
Sign up to access all valuation multiples
PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. It develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, which are image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. Geographically, the company generates a majority of its revenue from the United States and also has a presence in markets outside the U.S.
2021
756
LTM Revenue $266M
LTM EBITDA -$50.6M
$3.0B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
PROCEPT BioRobotics has a last 12-month revenue (LTM) of $266M and a last 12-month EBITDA of -$50.6M.
In the most recent fiscal year, PROCEPT BioRobotics achieved revenue of $224M and an EBITDA of -$82.0M.
PROCEPT BioRobotics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See PROCEPT BioRobotics valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $266M | XXX | $224M | XXX | XXX | XXX |
| Gross Profit | $166M | XXX | $137M | XXX | XXX | XXX |
| Gross Margin | 62% | XXX | 61% | XXX | XXX | XXX |
| EBITDA | -$50.6M | XXX | -$82.0M | XXX | XXX | XXX |
| EBITDA Margin | -19% | XXX | -37% | XXX | XXX | XXX |
| EBIT | -$93.4M | XXX | -$96.6M | XXX | XXX | XXX |
| EBIT Margin | -35% | XXX | -43% | XXX | XXX | XXX |
| Net Profit | -$88.2M | XXX | -$91.4M | XXX | XXX | XXX |
| Net Margin | -33% | XXX | -41% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, PROCEPT BioRobotics's stock price is $58.
PROCEPT BioRobotics has current market cap of $3.2B, and EV of $3.0B.
See PROCEPT BioRobotics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $3.0B | $3.2B | XXX | XXX | XXX | XXX | $-1.65 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, PROCEPT BioRobotics has market cap of $3.2B and EV of $3.0B.
PROCEPT BioRobotics's trades at 13.3x EV/Revenue multiple, and -36.3x EV/EBITDA.
Equity research analysts estimate PROCEPT BioRobotics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
PROCEPT BioRobotics has a P/E ratio of -36.4x.
See valuation multiples for PROCEPT BioRobotics and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $3.2B | XXX | $3.2B | XXX | XXX | XXX |
| EV (current) | $3.0B | XXX | $3.0B | XXX | XXX | XXX |
| EV/Revenue | 11.2x | XXX | 13.3x | XXX | XXX | XXX |
| EV/EBITDA | -58.8x | XXX | -36.3x | XXX | XXX | XXX |
| EV/EBIT | -31.9x | XXX | -30.8x | XXX | XXX | XXX |
| EV/Gross Profit | 18.0x | XXX | n/a | XXX | XXX | XXX |
| P/E | -36.4x | XXX | -35.1x | XXX | XXX | XXX |
| EV/FCF | -38.4x | XXX | -28.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialPROCEPT BioRobotics's last 12 month revenue growth is 38%
PROCEPT BioRobotics's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.3M for the same period.
PROCEPT BioRobotics's rule of 40 is -34% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
PROCEPT BioRobotics's rule of X is 76% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for PROCEPT BioRobotics and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 38% | XXX | 38% | XXX | XXX | XXX |
| EBITDA Margin | -19% | XXX | -37% | XXX | XXX | XXX |
| EBITDA Growth | -56% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -34% | XXX | 1% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 76% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 28% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 104% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
PROCEPT BioRobotics acquired XXX companies to date.
Last acquisition by PROCEPT BioRobotics was XXXXXXXX, XXXXX XXXXX XXXXXX . PROCEPT BioRobotics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was PROCEPT BioRobotics founded? | PROCEPT BioRobotics was founded in 2021. |
| Where is PROCEPT BioRobotics headquartered? | PROCEPT BioRobotics is headquartered in United States of America. |
| How many employees does PROCEPT BioRobotics have? | As of today, PROCEPT BioRobotics has 756 employees. |
| Who is the CEO of PROCEPT BioRobotics? | PROCEPT BioRobotics's CEO is Dr. Reza Zadno, PhD. |
| Is PROCEPT BioRobotics publicy listed? | Yes, PROCEPT BioRobotics is a public company listed on NAS. |
| What is the stock symbol of PROCEPT BioRobotics? | PROCEPT BioRobotics trades under PRCT ticker. |
| When did PROCEPT BioRobotics go public? | PROCEPT BioRobotics went public in 2021. |
| Who are competitors of PROCEPT BioRobotics? | Similar companies to PROCEPT BioRobotics include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of PROCEPT BioRobotics? | PROCEPT BioRobotics's current market cap is $3.2B |
| What is the current revenue of PROCEPT BioRobotics? | PROCEPT BioRobotics's last 12 months revenue is $266M. |
| What is the current revenue growth of PROCEPT BioRobotics? | PROCEPT BioRobotics revenue growth (NTM/LTM) is 38%. |
| What is the current EV/Revenue multiple of PROCEPT BioRobotics? | Current revenue multiple of PROCEPT BioRobotics is 11.2x. |
| Is PROCEPT BioRobotics profitable? | Yes, PROCEPT BioRobotics is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of PROCEPT BioRobotics? | PROCEPT BioRobotics's last 12 months EBITDA is -$50.6M. |
| What is PROCEPT BioRobotics's EBITDA margin? | PROCEPT BioRobotics's last 12 months EBITDA margin is -19%. |
| What is the current EV/EBITDA multiple of PROCEPT BioRobotics? | Current EBITDA multiple of PROCEPT BioRobotics is -58.8x. |
| What is the current FCF of PROCEPT BioRobotics? | PROCEPT BioRobotics's last 12 months FCF is -$77.4M. |
| What is PROCEPT BioRobotics's FCF margin? | PROCEPT BioRobotics's last 12 months FCF margin is -29%. |
| What is the current EV/FCF multiple of PROCEPT BioRobotics? | Current FCF multiple of PROCEPT BioRobotics is -38.4x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
